Cannabichromene Formulation for Non-Opioid Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management options, particularly opioids, come with side effects such as addiction and dependence, and there is a need for alternative formulations that can effectively replace opioid use without these drawbacks.
Innovation Solution
A cannabinoid formulation primarily containing cannabichromene (CBC) is developed, which can be used in various dosage forms and is free or contains minimal THC, potentially offering effective pain management without psychoactive effects by modulating DRD2 gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioids are used for pain management, then pain relief is achieved, but addiction and dependence occur
Solution Approach 1:
The patent changes the chemical parameter of the analgesic agent from opioid to cannabichromene, a cannabinoid compound that acts through different receptors (CB1 and CB2) in the endocannabinoid system. This parameter change in the active ingredient's molecular structure and mechanism of action provides pain relief through a non-opioid pathway, thereby eliminating opioid-induced addiction and dependence while maintaining analgesic effectiveness
Solution Approach 2:
The patent introduces cannabinoids as an intermediary substance that mediates pain relief through the endocannabinoid system rather than through opioid receptors. The cannabinoid compounds (particularly CBC) act as intermediaries that bind to CB1 and CB2 receptors, triggering analgesic effects without activating the opioid reward pathway that leads to addiction, thus serving as a safe intermediary between pain stimulus and relief response
2Reliability
If THC-containing formulations are used for pain management, then analgesic effects are achieved, but psychoactive side effects occur
Solution Approach 1:
The patent extracts and isolates cannabichromene (CBC) as the primary active ingredient from the cannabis plant, specifically excluding or minimizing THC content. By taking out only the non-psychoactive cannabinoid CBC and removing THC (the psychoactive component), the formulation achieves analgesic effects through CBC's action on CB1 and CB2 receptors without producing the intoxicating effects associated with THC
Solution Approach 2:
The patent segments the cannabinoid profile of cannabis by focusing exclusively on CBC and other non-psychoactive cannabinoids while excluding THC. This segmentation separates the therapeutic analgesic properties (attributed to CBC) from the psychoactive properties (attributed to THC), allowing the patent to harness only the beneficial pain-relieving effects without the harmful intoxicating effects
Data Source
AI summary
A method of opioid replacement is described which involves modulating the expression of dopaminergic genes (such as DRD2), as indicative of substance use disorders in individuals utilizing opioids and desirous of opioid replacement. Opioid replacement can involve a decrease in opioid seeking behavior of the subject, who may require pain management. A cannabinoid formulation is described comprising primarily cannabichromene (CBC) together with an excipient. A method is described for detecting the correlation between CBC treatment and downregulation of biomarkers of DRD2 gene expression. An effective non-psychoactive pain management therapy for opioid replacement is provided, as validated based on the gene expression profile of patients, where patient response to cannabichromene treatment can be predicted by such biomarkers. Such a therapy has the potential to reverse the transcriptional profile of DRD2 through tapering of opioid-induced upregulation, and/or through the potential downregulation of DRD2 expression.